COMMUNIQUÉS West-GlobeNewswire
-
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
31/03/2026 -
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026 -
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31/03/2026 -
Wildfire Smoke is Coming; Millions of Canadian Lungs Aren’t Ready
31/03/2026 -
Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026 -
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
31/03/2026 -
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31/03/2026 -
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31/03/2026 -
Betterbrand's BetterLungs Mullein + Chlorophyll Shows Significant Respiratory and Fatigue Improvements in 60-Day Clinical Study
31/03/2026 -
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
31/03/2026 -
Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1
31/03/2026 -
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
31/03/2026 -
Lighthouse Autism Center Opening New Autism Therapy Center in Rocky Mount, North Carolina
31/03/2026 -
TimelyCare Lands Fifth Straight Appearance on Inc. Fastest-Growing Companies in the Southwest list
31/03/2026 -
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03/2026 -
Mike Tyson and TerrAscend Expand TYSON 2.0 Footprint into Pennsylvania and Maryland
31/03/2026 -
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31/03/2026 -
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026 -
Global Medtech CDMO Market Grows to $96.5B in 2025 as Pharma-Medtech Convergence Emerges as a Defining Accelerator
31/03/2026
Pages